SK-BR-3
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
SK-BR-3 |
Humane Brust Adenokarzinom Zell-Linie |
300333 |
cryovial |
315,00 |
SK-BR-3 |
Humane Brust Adenokarzinom Zell-Linie |
330333 |
vital |
395,00 |
| Designation: | SK-BR-3 |
| Depositor: | Trempe |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 43 years old |
| Gender: | female |
| Tissue: | Breast; mammary gland (pleural effusion) |
| Morphology: | epithelial |
| Celltype: | adenocarcinoma; malignant |
| Growth Properties: | monolayer |
| Description: | Ultra structural features include microvilli and desmosomes, glycogen granules, large lysosomes, bundles of cytoplasmic fibrils. No virus particles. |
| Culture Medium: | DMEM supplemented with 1.5 mM L-glutamine and 10% fetal bovine serum. |
| Subculturing: | Remove medium, rinse with fresh 0.025% trypsin solution, remove trypsin and let the culture sit at room temperature (or at 37°C) until the cells detach. Add fresh medium, aspirate and dispense into new flasks. |
| Split Ratio: | A ratio of 1:2 to 1:4 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Negative in DAPI, MycoAlert and PCR for mycoplasma after treatment for 15 days with Mycokill (PAA Laboratories). Bacteria and fungi were negative. |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice; forms poorly differentiated adenocarcinoma |
| Karyotype: | (P9) hypertriploid to hypotetraploid (+A, +B, +C, +E, +F, +G, -D) with abnormalities including dicentrics, acrocentric fragments, rings, secondary constrictions, large metacentrics or polycentrics and large submetacentric marker |
| DNA Profile (STR): | Amelogenin: X,X CSF1PO: 12 D13S317: 11,12 D16S539: 9 D5S818: 9,12 D7S820: 9,12 THO1: 8,9 TPOX: 8,11 vWA: 17 D3S1358: 17 D21S11: 30,30.2 D18S51: 10,13 Penta E: 10,11 Penta D: 9,13 D8S1179: 11,12 FGA: 20 CLS ∙ Cell Lines Service, 2010. |
| Antigen Expression: | Blood Type A; Rh+; HLA A11, Bw22(+/-), B40, B18 |
| Isoenzymes: | PGM3, 1; PGM1, 1-2; ES-D, 1; AK-1, 1-2; GLO-1, 2; G6PD, B; Phenotype Frequency Product: 0.0044 |
References: Fogh J et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-14, 1977. Fogh J et al. One-hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 59: 221-6, 1977. Cameron DJ et al. Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators. J Clin Invest 63: 977-84, 1979. Pollack MS et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst 66: 1003-12, 1981. Chavany C et al. p185erbB2 binds to GRP94 in vivo. J Biol Chem 271: 4974-7, 1996. Littlewood-Evans AJ et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57: 5386-90, 1997. Wang X et al. Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. J Med Chem 49: 5631-4, 2006. Germershaus O et al. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expessing tumors. Bioconjug Chem 17: 1190-9, 2006. | |
